ESBL-producing bacteria total (n, %) | 17 | 24.3% |
ESBL E. coli | 16 | |
ESBL K. pneumoniae | 1 | |
Screening sites positive (n, %) | 17 | |
Footrests | 12 | 70.6% |
Door handles ± footrests | 5 | 29.4% |
Antibiotics resistant/intermediatea (n, %) | ||
Ampicillin | 17 | 100% |
Amoxicillin/Clavulanic acid | 16 | 94.1% |
Piperacillin/Tazobactam | 4 | 23.5% |
Cefoxitin | 11 | 64.7% |
Ceftazidime | 16 | 94.1% |
Ceftriaxone | 17 | 100% |
Cefepime | 16 | 94.1% |
Ertapenem | 0 | 0% |
Meropenem | 0 | 0% |
Ciprofloxacin | 16 | 94.1% |
Tobramycin | 15 | 88.2% |
Amikacin | 6 | 35.3% |
Trimethoprim/Sulfamethoxazole | 14 | 82.4% |
Nitrofurantoin | 1 | 5.9% |
Fosfomycin | 0 | 0% |
Colistin | 0 | 0% |
ESBL types (n, %) | 17 | |
CTX-M-1 group | 13 | 76.5% |
CTX-M-9 group | 1 | 5.9% |
Other than CTX-M-1/9 group | 3 | 17.6% |